The role of endothelin-1 in human hypertension

被引:1
作者
Shreenivas, Satya
Oparil, Suzanne
机构
[1] Univ Alabama Birmingham, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA
[2] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Endothelin-1 (ET-1) is a powerful vasoconstrictor and mitogen that contributes to blood pressure elevation and related vascular remodeling and target organ damage. ET-1 also influences salt and water homeostasis through effects on the renin-angiotensin-aldosterone system and vasopressin, thus elevating blood pressure and increasing vascular tone. Circulating ET-1 levels are elevated in a variety of animal models of hypertension, particularly those that are salt-dependent, and in a subset of human hypertensives, i.e. African-Americans and those with renal dysfunction. ET type B receptors, which normally have vasodilator functions, mediate vasoconstriction in some hypertensives, and hypertensive African-American patients may have increased numbers of vasoconstrictor ET-B receptors in their vascular smooth muscle. Whether selective ET-A or combined ET-A/ET-B receptor antagonists are more efficacious in treating hypertension and related cardiovascular disease is controversial. ET antagonists have only modest BP lowering effects in the general population of essential hypertensives, but show promise in patients with severe, treatment resistant hypertension.
引用
收藏
页码:157 / 178
页数:22
相关论文
共 114 条
[1]  
Abassi ZA, 2001, NEWS PHYSIOL SCI, V16, P152
[2]  
Abraham DJ, 1997, AM J PATHOL, V151, P831
[3]   Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction [J].
Amiri, F ;
Virdis, A ;
Neves, MF ;
Iglarz, M ;
Seidah, NG ;
Touyz, RM ;
Reudelhuber, TL ;
Schiffrin, EL .
CIRCULATION, 2004, 110 (15) :2233-2240
[4]   Altered expression of endothelin receptors in failing human left ventricles [J].
Asano, K ;
Bohlmeyer, TJ ;
Westcott, JY ;
Zisman, LS ;
Kinugawa, K ;
Good, M ;
Minobe, WA ;
Roden, RL ;
Wolfel, EE ;
Lindenfeld, J ;
Port, JD ;
Perryman, MB ;
Cleveland, J ;
Lowes, BD ;
Bristow, MR .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2002, 34 (07) :833-846
[5]   Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension - Open-label pilot study [J].
Barst, RJ ;
Rich, S ;
Widlitz, A ;
Horn, EM ;
McLaughlin, V ;
McFarlin, J .
CHEST, 2002, 121 (06) :1860-1868
[6]  
BATTISTINI B, 1993, LAB INVEST, V68, P600
[7]   Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension [J].
Bauer, M ;
Wilkens, HC ;
Langer, F ;
Schneider, SO ;
Lausberg, H ;
Schäfers, HJ .
CIRCULATION, 2002, 105 (09) :1034-1036
[8]   Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure [J].
Bauersachs, J ;
Fraccarollo, D ;
Galuppo, P ;
Widder, J ;
Ertl, G .
CARDIOVASCULAR RESEARCH, 2000, 47 (01) :142-149
[9]   Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia [J].
Best, PJM ;
McKenna, CJ ;
Hasdai, D ;
Holmes, DR ;
Lerman, A .
CIRCULATION, 1999, 99 (13) :1747-1752
[10]   Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-κB in human vascular smooth muscle cells [J].
Browatzki, M ;
Schmidt, J ;
Kübler, W ;
Kranzhöfer, R .
BASIC RESEARCH IN CARDIOLOGY, 2000, 95 (02) :98-105